NGL Fine-Chem Ltd
Company Profile
Business description
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
Contact
301, E Square, Subhash Road
Vile Parle (East)
MumbaiMH400057
INDT: +91 2240842222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
523
Stocks News & Analysis
stocks
Chart of the Week: Is CSL finally turning the ship around?
stocks
ASX top pick remains cheap with narrowing brand focus
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,861.70 | 96.20 | 1.10% |
| CAC 40 | 8,161.83 | 41.60 | -0.51% |
| DAX 40 | 24,195.31 | 237.75 | -0.97% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,254.81 | 27.48 | 0.27% |
| HKSE | 24,208.68 | 199.28 | -0.82% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 64,295.59 | 116.32 | 0.18% |
| NZX 50 Index | 13,182.99 | 70.66 | -0.53% |
| S&P 500 | 7,266.99 | 119.66 | -1.62% |
| S&P/ASX 200 | 8,661.50 | 98.00 | 1.14% |
| SSE Composite Index | 3,964.24 | 28.98 | -0.73% |